S-Enantiomer of the Antitubercular CompoundS006-830 Complements Activity of Frontline TB Drugs and Targets Biogenesisof Mycobacterium tuberculosis CellEnvelope

摘要

A synthetic molecule S006-830, belonging to the class of thiophene-containing trisubstituted methanes, had shown good in vitro and in vivo bactericidal activity against drug-sensitive and drug-resistant Mycobacterium tuberculosis (Mtb). The molecule had also shown good druglike pharmacokinetic properties. However, S006-830 is a racemic mixture of two enantiomers, one of which could possess a better pharmacological profile than the other. We purified both the enantiomers on a chiral column and observed that S-enantiomer has a significantly higher inhibitory and cidal activity against Mtb than the R-enantiomer. Action of S-S006-830 was “synergistic” for rifampicin and “additive” for isoniazid and ethambutol. The combination of S-S006-830 and rifampicin produced 100% kill of Mtb within 8 days. In a chemical proteomics approach using matrix-bound compound to pull down its target protein(s) from Mtb membrane, FabG4 (β-ketoacyl CoA reductase, EC 1.1.1.100) emerged as the most likely target for S-S006-830. In target validation assays, the compound exhibited 2-fold higherinhibitory concentration for an Mtb construct overexpressing FabG4.In addition, it inhibited mycolic acid biosynthesis and formationof biofilms by Mtb. Molecular docking of S-S006-830with FabG4 was consistent with the experimental data. These resultssupport the development of S-S006-830 as a novellead against tuberculosis.